As of January 22, 2025, Replimune (REPL) has a market cap of $1.00 billion USD. According to our data, Replimune is ranked No.5200 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $1.00 B |
7.51%
|
Dec 31, 2024 | $0.93 B |
43.65%
|
Dec 29, 2023 | $0.65 B |
-69.01%
|
Dec 30, 2022 | $2.09 B |
0.37%
|
Dec 31, 2021 | $2.09 B |
-28.96%
|
Dec 31, 2020 | $2.94 B |
165.85%
|
Dec 31, 2019 | $1.10 B |
43.50%
|
Dec 31, 2018 | $0.77 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
Bristol-Myers Squibb
BMY
|
$115.77 B |
0.000 M
|
USA
|
Merck
MRK
|
$242.01 B |
0.005 M
|
USA
|
Pfizer
PFE
|
$147.43 B |
0.004 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Novartis
NVS
|
$196.25 B |
0.003 M
|
Switzerland
|
AstraZeneca
AZN
|
$211.49 B |
0.007 M
|
UK
|
Johnson & Johnson
JNJ
|
$349.71 B |
-0.006 M
|
USA
|
Eli Lilly
LLY
|
$677.80 B |
-0.006 M
|
USA
|
Sanofi
SNY
|
$129.14 B |
0.001 M
|
France
|
GlaxoSmithKline
GSK
|
$68.21 B |
-0.002 M
|
UK
|
Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
Moderna
MRNA
|
$14.82 B |
-0.000 M
|
USA
|
Market Cap | = | REPL Stock Price | * | REPL Shares Outstanding |
= | $13.02 | * | 76.96 M | |
= | $1.00 B |